Stock Price, News, Quote and Profile of BIORA THERAPEUTICS INC(NASDAQ:BIOR) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIORA THERAPEUTICS INC

NASDAQ:BIOR (5/1/2024, 7:00:01 PM)

Premarket: 0.65 +0.01 (+1.25%)

0.642

-0.01 (-2.04%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap21.37M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 54 full-time employees. The company went IPO on 2020-06-19. The firm's therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP and BIOJET. NAVICAP is a targeted oral delivery platform of therapeutics to the site of disease in the GI tract, designed to improve outcomes for patients with inflammatory bowel disease (IBD). The NAVICAP drug delivery device is an investigational, clinical-stage, single-use ingestible device approximately the size of a fish oil capsule. BIOJET is a systemic oral delivery platform of biotherapeutics designed to replace injection with needle-free, oral delivery of molecules for better management of chronic diseases. The firm's targeted therapeutics pipeline programs include NAVICAP, BT-600 and BT-001. Its systemic therapeutics pipeline programs include BIOJET, BT-200 and BT-002.

Company Info

BIORA THERAPEUTICS INC

4330 La Jolla Village Drive, Suite 200

San Diego CALIFORNIA

P: 18552932639

Employees: 54

Website: https://www.bioratherapeutics.com/

BIOR News

2 days ago - Biora Therapeutics, Inc.Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

24 days ago - Biora Therapeutics, Inc.Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract

a month ago - Biora Therapeutics, Inc.Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed...

a month ago - Biora Therapeutics, Inc.Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery,...

BIORA THERAPEUTICS INC (BIOR)

Nasdaq Stock Screener

USA Stock Screener